BMS Urges FDA to Clarify Guidance on Risk-Based Trial Monitoring

Drug Industry Daily
A A
Bristol Myers Squibb has asked the FDA to clarify parts of its draft guidance for risk-based clinical trial monitoring.

To View This Article:

Login

Subscribe To Drug Industry Daily